arrow
K

Kenshi Suzuki

Japanese Red Cross Medical Center
H指数:46
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

达拉妥单抗联合硼替佐米、来那度胺和地塞米松在延迟移植的新诊断多发性骨髓瘤中的应用:CEPHEUS研究中的虚弱亚组分析

Leukemia
IF13.4
2026-08-180
OA
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS

达鲁珠单抗在移植不适用或延迟的 newly diagnosed multiple myeloma 中的研究:CEPHEUS 试验中的微小残留病

2026-06-050
OAAI
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

Daratumumab-硼替佐米-环磷酰胺-地塞米松治疗新诊断的淀粉样变性: 仙女座最终生存分析

Blood
IF23.1
2026-05-140
OAAI
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

维奈克拉或安慰剂联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤(BELLINI):一项随机、III期研究的最终总生存结果

2025-06-270
PRE
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma

人巨细胞病毒视网膜炎发生在接受伊达克塔格韦利塞特(Idecabtagene vicleucel)治疗的患者中,这些患者患有复发/难治性多发性骨髓瘤。

2025-04-210
PRE
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
2024-10-015
PRE
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
2024-01-122
OAAI
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)
2023-09-271
OAAI
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
2023-05-0944
OAAI
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA

Daratumumab联合硼替佐米,环磷酰胺和地塞米松在亚洲新诊断的AL淀粉样变性患者中的应用: 仙女座的亚组分析

2023-03-027
OAAI
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice
2023-02-142
OAAI